Non-Hodgkin Lymphoma by Clinical Course

Non-Hodgkin Lymphoma by Clinical Course — Trials · CancerIndex

Clinical trials

Registered studies

1,200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 346
Recruiting: 173
Ph III recruiting: 8
Growth YoY: +32.7%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (209)

clinicaltrialsPublishedShowing 151–200 of 629 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04433156	VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma	completed	Phase 2	26	Henan Cancer HospitalOTHER_GOV	1	Apr 9, 2026	clinicaltrials
NCT03697512	MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas(MALIBU)	active not recruiting	Phase 2	175	International Extranodal Lymphoma Study Group (IELSG)OTHER	5	Apr 8, 2026